Antitumor activity of IL-32β through the activation of lymphocytes, and the inactivation of NF-κB and STAT3 signals
Authors:
Open Access
- 23 May 2013
- journal article
- research article
- Published by Springer Nature in Cell Death & Disease
- Vol. 4 (5) , e640
Abstract
Cytokine and activation of lymphocytes are critical for tumor growth. We investigated whether interleukin (IL)-32β overexpression changes other cytokine levels and activates cytotoxic lymphocyte, and thus modify tumor growth. Herein, IL-32β inhibited B16 melanoma growth in IL-32β-overexpressing transgenic mice (IL-32β mice), and downregulated the expressions of anti-apoptotic proteins (bcl-2, IAP, and XIAP) and cell growth regulatory proteins (Ki-67 antigen (Ki-67) and proliferating cell nuclear antigen (PCNA)), but upregulated the expressions of pro-apoptotic proteins (bax, cleaved caspase-3, and cleaved caspase-9). IL-32β also inhibited colon and prostate tumor growth in athymic nude mice inoculated with IL-32β-transfected SW620 colon or PC3 prostate cancer cells. The forced expression of IL-32β also inhibited cell growth in cultured colon and prostate cancer cells, and these inhibitory effects were abolished by IL-32 small interfering RNA (siRNA). IL-10 levels were elevated, but IL-1β, IL-6, and tumor necrosis factor-alpha (TNF-α) levels were reduced in the tumor tissues and spleens of IL-32β mice, and athymic nude mice. The number of cytotoxic T (CD8+) and natural killer (NK) cells in tumor tissues, spleen, and blood was significantly elevated in IL-32β mice and athymic nude mice inoculated with IL-32β-transfected cancer cells. Constituted activated NF-κB and STAT3 levels were reduced in the tumor tissues of IL-32β mice and athymic nude mice, as well as in IL-32β-transfected cultured cancer cells. These findings suggest that IL-32β inhibits tumor growth by increasing cytotoxic lymphocyte numbers, and by inactivating the NF-κB and STAT3 pathways through changing of cytokine levels in tumor tissues.Keywords
This publication has 55 references indexed in Scilit:
- IL-32γ inhibits cancer cell growth through inactivation of NF-κB and STAT3 signalsOncogene, 2011
- Inhibitor of κB Kinase Beta Regulates Gastric Carcinogenesis via Interleukin-1α ExpressionGastroenterology, 2010
- Guidelines for the welfare and use of animals in cancer researchBritish Journal of Cancer, 2010
- aPKCλ/ι promotes growth of prostate cancer cells in an autocrine manner through transcriptional activation of interleukin-6Proceedings of the National Academy of Sciences, 2009
- Inflammation and Cancer: IL-6 and STAT3 Complete the LinkCancer Cell, 2009
- Is NF-κB a good target for cancer therapy? Hopes and pitfallsNature Reviews Drug Discovery, 2009
- Cancer-related inflammationNature, 2008
- Intratumoral cytokines/chemokines/growth factors and tumor infiltrating dendritic cells: friends or enemies?Cancer and Metastasis Reviews, 2006
- NF-κB in cancer: from innocent bystander to major culpritNature Reviews Cancer, 2002
- The Hallmarks of CancerCell, 2000